APA (7th ed.) Citation

P, M., H, P., S, G., I, K., X, L., G, R., . . . B, A. (2015). Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: Subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica, 100(5), e207. https://doi.org/10.3324/haematol.2014.118182

Chicago Style (17th ed.) Citation

P, Moreau, et al. "Subcutaneous Versus Intravenous Bortezomib in Patients with Relapsed Multiple Myeloma: Subanalysis of Patients with Renal Impairment in the Phase III MMY-3021 Study." Haematologica 100, no. 5 (2015): e207. https://doi.org/10.3324/haematol.2014.118182.

MLA (9th ed.) Citation

P, Moreau, et al. "Subcutaneous Versus Intravenous Bortezomib in Patients with Relapsed Multiple Myeloma: Subanalysis of Patients with Renal Impairment in the Phase III MMY-3021 Study." Haematologica, vol. 100, no. 5, 2015, p. e207, https://doi.org/10.3324/haematol.2014.118182.